Liver: Combined hepatocellular and cholangiocarcinoma

2007-09-01   Munechika Enjoji , Shinichi Aishima 

1.Department of Hepatology, Pancreatology, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan (ME); Department of Pathology, Hamanomachi Hospital, 3-5-27 Maizuru, Chuo-ku, Fukuoka 810-8539, Japan (SA)

Summary

Note

Defined as an intrahepatic tumor nodule that contains both hepatocellular carcinoma and cholangiocarcinoma.

Classification

Note

Tumor staging is separated by TNM classification.

Classification

TNM classifications for hepatocellular and cholangiocarcinomas of the liver.

Clinics and Pathology

Etiology

The reported frequency of combined hepatocellular and cholangiocarcinoma (combined tumors) varies widely; 1.0-6.5% among patients with primary liver cancer. Statistical data indicate that combined tumors occur predominantly in men (reported ratio is ranged from 14:1 to 2:1). The mean age of onset is in the sixth decade. In Asian cases, a high incidence of hepatitis B or C virus infection and frequent association of chronic liver disease/cirrhosis have been reported. Conversely, in Western countries, these features are less common. Combined tumors exhibit an invasive character with frequent venous permeation and tumor microsatellite formation, features that are seen more frequently than in ordinary HCC.

Epidemiology

A rare subtype of primary liver cancer.

Clinics

The typical clinical symptom is abdominal pain. Complaints of fatigue and weakness are mostly attributable to compromised liver function. Jaundice is found in a much lower percentage of patients than of those with intrahepatic cholangiocarcinoma (CC). Chills and fever appear rarely.
In combined tumors, HCC and CC areas rarely can be identified using imaging techniques such as ultrasonography, helical CT, and dynamic MRI. In many cases, even in tumor biopsy samples, the two components are not included or discriminated. Generally, final diagnosis is entrusted to pathological findings of surgically resected or autopsy samples.

Pathology

The histopathological classification reported by Goodman et al. is popular:
  • type I, in which HCC and CC occur coincidentally and no transitional forms are observed;
  • type II, in which there are areas of apparent transition between HCC and CC;
  • type III, in which tumor cells resemble the fibrolamellar subtype of HCC but contain mucin-producing glands.
    Other classifications, reported by Allen and Lisa, and by Kojiro et al., are known.
  • Atlas Image
    (A and B) Gross feature and schematic illustration of combined hepatocellular and cholangiocarcinoma. HCC: hepatocellular carcinoma, CC: cholangiocarcinoma. (C-E) Border zone between HCC and CC. Moderately differentiated HCC (right) with vague grandular component (left). The grandular tumor cells were positive for CK19 and HCC component was positive for Hep par-1.

    Treatment

    Surgical resection, chemotherapy, radiofrequency ablation, microwave coagulation, ethanol injection, transarterial embolization.

    Evolution

    Intrahepatic recurrence is common. Combined tumors have been reported to be more aggressive than HCC, with widespread metastasis and regional lymph node involvement.

    Prognosis

    The prognosis of combined tumors is poorer than that of HCC because of relatively frequent lymph node metastasis and vascular invasion. Survival rates of patients with combined tumors are generally poorer than those of patients with HCC.

    Cytogenetics

    Note

    Loss of heterozygosity (LOH) at 4q, 8p, 13q, 16q, and 17p is seen frequently in combined hepatocellular and cholangiocarcinoma similar to in HCC. LOH at 3p and 14q are reported to be specific in CC and combined hepatocellular-cholangiocarcinoma in contrast to HCC.

    Genes Involved and Proteins

    Gene name

    KRAS (Kirsten rat sarcoma 2 viral oncogene homolog)

    Location

    12p12.1

    Dna rna description

    4 exons

    Protein description

    Proto-oncogene. GTP-GDP binding protein with GTPase activity. The K-ras proto-oncogene is thought to exert control over some of the mechanisms of cell growth and differentiation. This gene is converted to an active oncogene by point mutations concentrated significantly in codons 12, 13, and 61.
    Mutations of the K-ras gene have been reported to be common (67-75%) in intrahepatic CC. Conversely, the mutations rarely have been found in HCC. K-ras mutations in combined hepatocellular and cholangiocarcinoma have been analyzed in Japanese cases and it has been reported that the mutations were found rarely, as in the case for HCC. This observation may reflect the background of Japanese patients; specifically, chronic hepatitis C infection and evidence of cirrhosis are found in a relatively high percentage of patients with combined hepatocellular and cholangiocarcinoma.

    Gene name

    TP53 (Tumour protein p53 (Li-Fraumeni syndrome))

    Location

    17p13.1

    Dna rna description

    11 exons

    Protein description

    Tumor suppressor. Wild-type p53 plays an important role in the regulation of the cell cycle process, cell growth, and apoptosis in the event of DNA damage. The aberrant proteins from the mutated genes disrupt critical growth-regulating mechanisms and may play a crucial role in the carcinogenesis. The reported incidence of p53 mutation is 11-37% in intrahepatic CC and 10-29% in combined hepatocellular and cholangiocarcinoma. In HCC, the frequency of p53 mutations varies among different geographic areas. p53 abnormalities appear not to be correlated with tumoral differentiation.

    Bibliography

    Pubmed IDLast YearTitleAuthors
    181528601949Combined liver cell and bile duct carcinoma.ALLEN RA et al
    166133232006Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma.Aishima S et al
    152884792004Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.Cazals-Hatem D et al
    171394282006Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.Chantajitr S et al
    110145642000Genetic classification of combined hepatocellular-cholangiocarcinoma.Fujii H et al
    25780781985Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study.Goodman ZD et al
    89570641996Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hapatocellular-cholangiocellular carcinomas.Imai Y et al
    119329072002Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors.Jarnagin WR et al
    157015042005Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma.Koh KC et al
    123977142002Comparing combined hepatocellular-cholangiocarcinoma and cholangiocarcinoma: a clinicopathological study.Lee CC et al
    169986832006Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.Lee WS et al
    170729462006Hepatic progenitor cells in human liver tumor development.Libbrecht L et al
    75456441995Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features.Maeda T et al
    97375691998Combined hepatocellular-cholangiocarcinoma: a clinicopathological study.Ng IO et al
    88727741996A clinicopathological study on combined hepatocellular and cholangiocarcinoma.Taguchi J et al
    13366661992Cholangiocarcinomas in Japanese and Thai patients: difference in etiology and incidence of point mutation of the c-Ki-ras proto-oncogene.Tsuda H et al
    175233092007A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.Wakasa T et al
    129130822003Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases.Yano Y et al
    173745752007Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.Zuo HQ et al

    Citation

    Munechika Enjoji ; Shinichi Aishima

    Liver: Combined hepatocellular and cholangiocarcinoma

    Atlas Genet Cytogenet Oncol Haematol. 2007-09-01

    Online version: http://atlasgeneticsoncology.org/solid-tumor/5331/liver-combined-hepatocellular-and-cholangiocarcinoma